|
Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma Clinical research trials and Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma. Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma clinical trial. Participants oftentimes recieve the most expert healthcare available for their Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma  Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma
Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma
For Condition: Lymphoma, Small Lymphocytic,Lymphoma, Low-Grade,Lymphoma, Mixed-Cell, Follicular,Lymphoma, Small Cleaved-Cell, Follicular
Status: Recruiting
Sponsor(s): Novuspharma ,
Synopsis: The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination’s safety and activity profile.
Details: The FND-R regimen is commonly used in the treatment of indolent Non-Hodgkin’s lymphoma (NHL) and contains the chemotherapy agents mitoxantrone, fludarabine, dexamethasone (a steroid) and the monoclonal antibody rituximab. In this trial we are replacing mitoxantrone with pixantrone, an agent with a similar chemical structure (both agents are DNA intercalators). The trial is being run in patients with relapsed or refractory indolent NHL and aims to define the appropriate dose of pixantrone to be used in this combination, as well as to obtain data on pixantrone’s safety and activity profile in combination with these drugs. This trial is expected to recruit up to 30 patients in the USA. Patients will be treated with the drug combination for up to eight months and then followed closely in the four-week period after the last administration. After that, patients will receive physician check-ups every three months.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion criteria - Patients with relapsed or refractory indolent (low-grade) NHL - Who have received 1-3 prior treatments with chemotherapy Exclusion criteria - Patients previously treated with fludarabine - Prior treatment with rituximab (Rituxan), unless there was a complete response (CR) or partial response (PR) to that treatment *Patients known to have an allergic reaction to rituximab, or to murine proteins.
Total Enrollment: 30
Location and Contact Information:
Greater Baltimore Medical Center *Recruiting*
Baltimore, Maryland, 21204
United States
Recruiting Lauren Titus 443-849-3285
Arizona Clinical Research Center *Recruiting*
Tucson, Arizona, 85712
United States
Recruiting Jarret Schonbrun 520-290-2510
New Mexico Onc/Hem Consultants, Inc. *Recruiting*
Albuquerque, New Mexico, 87109
United States
Recruiting Patti Hopper 505-243-4039
MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Yolanda Arredondo 713-745-2720
Additional Information:
Study ID Numbers: AZA I-06;
Study Start Date:
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00060684
Other Lymphoma, Mixed-Cell, Follicular Studies:
1. Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma
2. Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma
Related Studies:
Other Lymphoma, Mixed-Cell, Follicular Clinical Trials
Other Maryland Clinical Trials
Other Baltimore Clinical Trials
Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma
|
|
|
|
|
|
|
|
